Hyderabad, Aug.5 (NSS): The Drug Discovery & Development Workshop, currently unfolding virtually and organized by Federation of Asian Biotech Associations (FABA), University of Hyderabad and Science Guru, marked its third day with captivating presentations that are setting new standards in the fields of pharmacology and biotechnology. The event is a cornerstone of the global biotech community’s calendar, featuring over 40 experts from diverse backgrounds.
Highlighting the day was Dr Vaishnavi Ganti from Gilead Sciences, who provided deep insights into the optimization of dosing regimens for biologics in oncology. Dr Ganti discussed cutting-edge strategies to maximize efficacy and minimize side effects, including body weight-based capping and response-guided dosing. Her focus on advanced pharmacokinetic and pharmacodynamic modeling is shaping the future of personalized medicine in oncology treatment.
Dr Mukesh Kumar Gupta of NARFBR discussed the revolutionary changes in preclinical trials brought about by ethical animal model research. His talk covered the significant strides made towards more humane and scientifically enhanced animal studies, which are crucial for the safety and efficacy of new drug developments. Dr Gupta’s emphasis on ethical guidelines reflects the industry’s commitment to responsible biopharmaceutical research.
Dr K. S. Rao from Adgyl Life Sciences, explored the importance of allergy testing and toxicology in drug development. He detailed the rigorous process of bringing a new drug to market, from initial discoveries through to regulatory approvals, underscoring the need for ongoing innovation and adaptation in drug safety studies.
The workshop attracted a wide array of attendees, from budding scientists to seasoned professionals, all eager to discuss, learn, and collaborate on the pressing issues facing drug discovery and development.
